Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination

American Journal of Epidemiology

Volumn 178, Issue 4, 2013, Pages 625-634

  Tota, Joseph E ^a,b   Ramanakumar, Agnihotram V ^a   Jiang, Mengzhu ^a   Dillner, Joakim ^c   Walter, Stephen D ^d   Kaufman, Jay S ^b   Coutlée, François ^e   Villa, Luisa L ^f   Franco, Eduardo L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cervical cancer; HPV type replacement; human papillomavirus; vaccination

Indexed keywords

DNA; WART VIRUS VACCINE;

EPIDEMIOLOGY; VACCINATION; VACCINE; VIRUS;

ARTICLE; CANCER RISK; DRUG EFFICACY; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; MIXED INFECTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTOR; UTERINE CERVIX CANCER; VACCINATION; VIRUS LOAD; WART VIRUS;

CERVICAL CANCER; HPV TYPE REPLACEMENT; HUMAN PAPILLOMAVIRUS; VACCINATION;

COINFECTION; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROPORTIONAL HAZARDS MODELS; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 84881568215     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt018     Document Type: Article

References (70)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
2. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367(9518):1247-1255.
3. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-935.
4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen The international perspective. Int J Cancer. 2004;111(2):278-285.
5. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
6. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927-935.
7. Mendez F, Munoz N, Posso H, et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis. 2005;192(7):1158-1165.
8. Rousseau MC, Pereira JS, Prado JC, et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001;184(12):1508-1517.
9. Martcheva M, Bolker BM, Holt RD. Vaccine-induced pathogen strain replacement: what are the mechanisms J R Soc Interface. 2008;5(18):3-13.
10. Dillner J, Arbyn M, Unger E, et al. Monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2011; 163(1):17-25.
11. Franco E, Villa L, Rohan T, et al. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999;6(4):223-233.
12. Porta M. The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low Prev Med. 2009; 48(5):407-410.
13. Obaro SK, Adegbola RA, BanyaWA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348(9022):271-272.
14. Dagan R, Muallem M, Melamed R, et al. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J. 1997;16(11):1060-1064.
15. Mbelle N, Huebner RE,Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999; 180(4):1171-1176.
16. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007; 297(16):1784-1792.
17. Bernard HU. Coevolution of papillomaviruses with human populations. Trends Microbiol. 1994;2(4):140-143.
18. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73.
19. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
20. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-79.
21. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol. 1992;73(10):2653-2660.
22. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8.
23. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
24. Gause GF. The Struggle for Existence. Baltimore, MD: Williams &Wilkins; 1934.
25. Poolman EM, Elbasha EH, Galvani AP. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine. 2008;26(suppl 3):C25-C30.
26. Wheeler CM, Castellsague X, Garland SM, et al. Crossprotective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-110.
27. Villa LL, Franco EL. Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil. J Natl Cancer Inst. 1989; 81(5):332-340.
28. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis. 2000;182(4):1097-1102.
29. Rousseau MC, Villa LL, Costa MC, et al. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis. 2003;30(7):581-587.
30. Chaturvedi AK, Myers L, Hammons AF, et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2439-2445.
31. Mejlhede N, Pedersen BV, Frisch M, et al. Multiple human papilloma virus types in cervical infections: competition or synergy APMIS. 2010;118(5):346-352.
32. Vaccarella S, Franceschi S, Snijders PJ, et al. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev. 2010;19(2):503-510.
33. Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011; 203(7):910-920.
34. Vaccarella S, Franceschi S, Herrero R, et al. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis. 2011;204(3):385-390.
35. Vaccarella S, Plummer M, Franceschi S, et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in Men (HIM) Study. J Infect Dis. 2011;204(10): 1500-1504.
36. Rositch AF, Poole C, Hudgens MG, et al. Multiple human papillomavirus infections and type competition in men. J Infect Dis. 2012;205(1):72-81.
37. Rousseau MC, Franco EL, Villa LL, et al. A cumulative casecontrol study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev. 2000;9(5):469-476.
38. Rousseau MC, Abrahamowicz M, Villa LL, et al. Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2003;12(10): 1029-1037.
39. Clifford GM, Gallus S, Herrero R, et al.Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991-998.
40. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001; 183(1):8-15.
41. Plummer M, Vaccarella S, Franceschi S. Multiple human papillomavirus infections: the exception or the rule J Infect Dis. 2011;203(7):891-893.
42. Nielsen A, Kjaer SK, Munk C, et al. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis. 2008;35(3):276-282.
43. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(suppl 1): S16-S24.
44. Mejlhede N, Bonde J, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS. 2009;117(2):108-114.
45. Oliveira LH, Rosa ML, Cavalcanti SM. Patterns of genotype distribution in multiple human papillomavirus infections. Clin Microbiol Infect. 2008;14(1):60-65.
46. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000;29(1):158-167.
47. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol. 2000;151(5):531-539.
48. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582-1589.
49. Gravitt PE, Manos MM. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA. IARC Sci Publ. 1992;(119):121-133.
50. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44(9):3292-3298.
51. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
52. Coutlee F, Gravitt P, Kornegay J, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol. 2002;40(3):902-907.
53. Chan PK, Cheung TH, Tam AO, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer. 2006;118(1):243-245.
54. Depuydt CE, Boulet GA, Horvath CA, et al. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med. 2007; 11(4):881-891.
55. Lin CY, Chao A, Yang YC, et al. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J Clin Virol. 2008; 42(4):361-367.
56. Klug SJ, Molijn A, Schopp B, et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol. 2008;80(7):1264-1274.
57. Soderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol. 2009; 47(3):541-546.
58. Schmitt M, Dondog B, Waterboer T, et al. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J ClinMicrobiol. 2010;48(1):143-149.
59. Mori S, Nakao S, Kukimoto I, et al. Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci. 2011;102(6):1223-1227.
60. Eklund C, Zhou T, Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010; 48(11):4147-4155.
61. Eklund C, Forslund O,Wallin KL, et al. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol. 2012;50(7):2289-2298.
62. Lipsitch M. Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccineinduced increases in carriage of nonvaccine serotypes. Am J Epidemiol. 2001;154(1):85-92.
63. Frazao N, Sa-Leao R, de Lencastre H. Impact of a single dose of the 7-valent pneumococcal conjugate vaccine on colonization. Vaccine. 2010;28(19):3445-3452.
64. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet. 2007;369(9580): 2161-2170.
65. Wheeler CM. Less is more: a step in the right direction for human papillomavirus (HPV) vaccine implementation. J Natl Cancer Inst. 2011;103(19):1424-1425.
66. van der Marel J, Quint WG, Schiffman M, et al. Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer. 2012;131(6): E946-E953.
67. Hedlund J. Risky business: safety regulations, risks compensation, and individual behavior. Inj Prev. 2000;6(2): 82-90.
68. Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012;42(1): 44-52.
69. Cho HJ, Oh YK, Kim YB. Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat. 2011; 21(2):295-309.
70. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst. 2011;103(5): 360-362.